Literature DB >> 21765702

The application of antisense technology to medicine.

R Re1.   

Abstract

Year:  2000        PMID： 21765702      PMCID： PMC3117510     

Source DB:  PubMed          Journal:  Ochsner J        ISSN： 1524-5012


× No keyword cloud information.
  16 in total

Review 1.  Antisense therapeutics: is it as simple as complementary base recognition?

Authors:  S Agrawal; E R Kandimalla
Journal:  Mol Med Today       Date:  2000-02

2.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.

Authors:  S M Hammond; E Bernstein; D Beach; G J Hannon
Journal:  Nature       Date:  2000-03-16       Impact factor: 49.962

3.  Potent growth inhibition of leukemic cells by novel ribbon-type antisense oligonucleotides to c-myb1.

Authors:  I J Moon; K Choi; Y K Choi; J E Kim; Y Lee; A D Schreiber; J G Park
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

4.  Antisense therapeutics in oncology: points to consider in their clinical evaluation.

Authors:  S Mani; Y Gu; S Wadler; H Fingert
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1999-12

5.  Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

Authors:  G Pagnan; D D Stuart; F Pastorino; L Raffaghello; P G Montaldo; T M Allen; B Calabretta; M Ponzoni
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

6.  Molecular structure of nucleic acids. A structure for deoxyribose nucleic acid. 1953.

Authors:  J D Watson; F H Crick
Journal:  Ann N Y Acad Sci       Date:  1995-06-30       Impact factor: 5.691

7.  Suppression of cellular proliferation using p53 DNA recognition site-related oligonucleotides.

Authors:  R N Ré; J L Cook
Journal:  Am J Med Sci       Date:  1996-02       Impact factor: 2.378

8.  Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis.

Authors:  M Murano; K Maemura; I Hirata; K Toshina; T Nishikawa; N Hamamoto; S Sasaki; O Saitoh; K Katsu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

9.  Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors.

Authors: 
Journal:  Cancer Control       Date:  1998-03       Impact factor: 3.302

10.  Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynucleotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts.

Authors:  B T Feeley; R S Poston; A K Park; M P Ennen; E G Hoyt; P W Vriens; R C Robbins
Journal:  Transplantation       Date:  2000-03-27       Impact factor: 4.939
View more
  2 in total

1.  Recent publications by ochsner authors.

Authors: 
Journal:  Ochsner J       Date:  2001-04

Review 2.  Credible Protein Targets and Curative Strategies for COVID-19: a Review.

Authors:  Priya Singh; Nidhi Mishra; Neelu Singh; Raquibun Nisha; Ravi Raj Pal; Samipta Singh; Priyanka Maurya; Shubhini A Saraf
Journal:  SN Compr Clin Med       Date:  2020-09-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.